Provectus Pharmaceuticals Inc. Submits Application To FDA To Receive Breakthrough Therapy Designation For PV-10 For Treatment Of Melanoma
3/24/2014 8:10:21 AM
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that the Agency will make a decision on the application within 60 days of receipt. The Agency’s records for FY 2013 show that the Agency’s Center for Drug Evaluation and Research (CDER) met that guideline 97% of the time.
Help employers find you! Check out all the jobs and post your resume.
comments powered by